Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses Meeting Abstract


Authors: Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
Abstract Title: Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses
Meeting Title: 2025 ASCO Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 43
Issue: 5 Suppl.
Meeting Dates: 2025 Feb 13-15
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2025-02-10
Language: English
ACCESSION: WOS:001454684700019
DOI: 10.1200/JCO.2025.43.5_suppl.540
PROVIDER: wos
Notes: Meeting Abstract: 540 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1251 Motzer
  2. Darren Richard Feldman
    348 Feldman
  3. Martin Henner Voss
    294 Voss
  4. Maria Isabel Carlo
    168 Carlo
  5. Andrea Knezevic
    109 Knezevic
  6. Ritesh Rajesh Kotecha
    95 Kotecha
  7. Neil Jayendra Shah
    93 Shah
  8. Sahil Deepak Doshi
    20 Doshi